🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Safety and Modulation of Adaptive Immunity by Iscador® Qu Viscum Album Extract in Patients With Advanced, Recurrent or Metastatic Cancers Treated With Immune Checkpoint Inhibitors

RecruitingPhase 4Ages 18 Years - anyAllUniversity Hospital, Basel, Switzerland
NCT06408688 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The main objective of this study is to test if adding the mistletoe extract Iscador® Qu to regular cancer treatment with immune checkpoint inhibitors affects: * The immune system's ability to fight cancer * Safety of the treatment * How well the treatment performs against cancer * How the patient feels during treatment Researchers will compare patients treated with immune checkpoint inhibitors plus Iscador® Qu with patients treated with imune checkpoint inhibitors only.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Locally advanced non-operable or metastatic solid tumor, except for skin cancer * Eligible for routine (standard) treatment with immune checkpoint inhibitor (+/- chemo/targeted therapy) as per the discretion of the local investigator * Subjects must be eligible for treatment with mistletoe preparations (controlled brain metastases, prednisolone equivalent below 10mg, no known hypersensitivity) * ECOG (Eastern Cooperative Oncology Group) performance status score of 0-2 * Males and Females at least 18 years of age; no subjects under tutelage * No previous mistletoe treatment Exclusion Criteria: * Contraindications to Iscador® Qu or immune checkpoint inhibitors, e.g. hypersensitivity, active autoimmune disorder * Patients with skin cancer * Participation in another study with investigational drug within 30 days prior to enrolment (participation in observational studies or diagnostic studies without a particular drug intervention are allowed) * Enrolment of the investigator, his/her family members, employees and other dependent
💊

What it tests

  • Immune checkpoint inhibitors plus Iscador® Qu.
  • Immune Checkpoint Inhibitors
📍

Where

4 sites
Kantosspital Baden AG
Baden, Switzerland
Universitätsspital Basel
Basel, Switzerland
Kantonsspital Baselland
Liestal, Switzerland
Tumor- und Brustzentrum Ostschweiz
Sankt Gallen, Switzerland
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy